InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (11 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
11
T+90 hit rate
0%
T+90 mean return
-21.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Sethuraman Natarajan, President, Research & Develop.. Officer active across 1 company, notably Entrada Therapeutics, Inc.. In total, 19 disclosures have been recorded. Breakdown: 0 buy · 11 sells. Total volume traded: €879k. Activity tracked since 1 March 2022. The latest transaction was disclosed on 4 May 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations19 total
▼
25,907 shares@ US$15.39390.14% mcap50.0% of flowCommon StockSEC:0001873394-26-000003
▼
25,907 shares@ US$15.39390.14% mcap50.0% of flowCommon StockSEC:0001873394-26-000003:0
60,800 shares0Common StockSEC:0001689375-25-000012:0
▼
100 shares@ US$20.000.2% of flowCommon StockSEC:0001689375-24-000067:0
▼
1,409 shares@ US$20.00793.0% of flowCommon StockSEC:0001689375-24-000066:0
▼
749 shares@ US$18.0221.4% of flowCommon StockSEC:0001689375-24-000064:0
▼
600 shares@ US$18.001.1% of flowCommon StockSEC:0001689375-24-000057:0
600 shares@ US$15.23560.9% of flowCommon StockSEC:0001689375-24-000053:0
469 shares@ US$15.76110.8% of flowCommon StockSEC:0001689375-24-000050:0
600 shares@ US$18.001.1% of flowCommon StockSEC:0001689375-24-000041:0
1,000 shares@ US$15.001.6% of flowCommon StockSEC:0001689375-24-000031:0
44,100 shares0Common StockSEC:0001689375-24-000003:0
14,200 shares0Common StockSEC:0001689375-23-000063:0
3,026 shares@ US$18.0025.6% of flowCommon StockSEC:0001689375-23-000046:0
14,200 shares0Common StockSEC:0001689375-23-000029:0
3,961 shares@ US$18.00457.4% of flowCommon StockSEC:0001689375-23-000031:0
28,400 shares0Common StockSEC:0001689375-23-000014:0
5,794 shares0Common StockSEC:0001104659-22-097876:0
11,588 shares0Common StockSEC:0001104659-22-030008:0
19 of 19 declarations
About Sethuraman Natarajan
Sethuraman Natarajan is President of Research & Development and Chief Scientific Officer at Entrada Therapeutics, Inc. He is responsible for leading the company's research and development operations. With extensive experience in the biopharmaceutical sector, Sethuraman plays a key role in innovation and developing new treatments to meet patient needs.
